安進(AMGN.US)AMG 133啓動減重III期臨牀

智通財經

2025/03/07

智通財經APP獲悉，3月5日，全球臨牀試驗收錄網站clinicaltrials顯示，安進(AMGN.US)啓動了AMG 133(Maridebart Cafraglutide，MariTide)的兩項III期臨牀試驗(MARITIME-1和MARITIME-2)，標誌着AMG 133進入III期開發階段。

AMG133是安進自主研發的一款注射頻率可達到每4周1次的first-in-class抗體多肽偶聯藥物，由靶向葡萄糖依賴性促胰島素釋放多肽受體(GIPR)的全人源單抗偶聯兩個GLP-1類似物而成，通過抑制GIPR並激活GLP-1受體(GLP-1R)來發揮減少食物攝入和調節代謝進而減輕體重和降低血糖的作用。

AMG 133的降糖和減重效果已經在II期研究中得到了初步驗證。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2517175213"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517175213\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2517175213?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-03-07 15:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517175213","market":"us","top_or_hot":-1,"title":"安進(AMGN.US)AMG 133啓動減重III期臨牀","media":"智通財經","content":"<html><body><p>智通財經APP獲悉，3月5日，全球臨牀試驗收錄網站clinicaltrials顯示，<a href=\"https://laohu8.com/S/AMGN\">安進</a>(AMGN.US)啓動了AMG 133(Maridebart Cafraglutide，MariTide)的兩項III期臨牀試驗(MARITIME-1和MARITIME-2)，標誌着AMG 133進入III期開發階段。</p><p>AMG133是安進自主研發的一款注射頻率可達到每4周1次的first-in-class抗體多肽偶聯藥物，由靶向葡萄糖依賴性促胰島素釋放多肽受體(GIPR)的全人源單抗偶聯兩個GLP-1類似物而成，通過抑制GIPR並激活GLP-1受體(GLP-1R)來發揮減少食物攝入和調節代謝進而減輕體重和降低血糖的作用。</p><p>AMG 133的降糖和減重效果已經在II期研究中得到了初步驗證。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>安進(AMGN.US)AMG 133啓動減重III期臨牀</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n安進(AMGN.US)AMG 133啓動減重III期臨牀\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2025-03-07 15:29</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p>智通財經APP獲悉，3月5日，全球臨牀試驗收錄網站clinicaltrials顯示，<a href=\"https://laohu8.com/S/AMGN\">安進</a>(AMGN.US)啓動了AMG 133(Maridebart Cafraglutide，MariTide)的兩項III期臨牀試驗(MARITIME-1和MARITIME-2)，標誌着AMG 133進入III期開發階段。</p><p>AMG133是安進自主研發的一款注射頻率可達到每4周1次的first-in-class抗體多肽偶聯藥物，由靶向葡萄糖依賴性促胰島素釋放多肽受體(GIPR)的全人源單抗偶聯兩個GLP-1類似物而成，通過抑制GIPR並激活GLP-1受體(GLP-1R)來發揮減少食物攝入和調節代謝進而減輕體重和降低血糖的作用。</p><p>AMG 133的降糖和減重效果已經在II期研究中得到了初步驗證。</p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.zhitongcaijing.com/content/detail/1258992.html\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持倉","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1258992.html","article_id":"2517175213","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517175213","pubTimestamp":1741332593,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通財經APP獲悉，3月5日，全球臨牀試驗收錄網站clinicaltrials顯示，安進啓動了AMG 133的兩項III期臨牀試驗，標誌着AMG 133進入III期開發階段。AMG133是安進自主研發的一款注射頻率可達到每4周1次的first-in-class抗體多肽偶聯藥物，由靶向葡萄糖依賴性促胰島素釋放多肽受體的全人源單抗偶聯兩個GLP-1類似物而成，通過抑制GIPR並激活GLP-1受體來發揮減少食物攝入和調節代謝進而減輕體重和降低血糖的作用。AMG 133的降糖和減重效果已經在II期研究中得到了初步驗證。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4581":"高盛持仓","BK4599":"减肥药","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","AMGN":"安进","AMG":"Affiliated Managers Group Inc","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4505":"高瓴资本持仓","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","III":"信息服务","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4135":"资产管理与托管银行","LU0058720904.USD":"联博国际健康护理基金A","BK4588":"碎股","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4134":"信息科技咨询与其它服务","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC"},"translate_title":"Amgen (AMGN.US) AMG 133 initiates phase III clinical trial for weight loss","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1,"AMGN":1,"AMG":1},"content_text":"智通財經APP獲悉，3月5日，全球臨牀試驗收錄網站clinicaltrials顯示，安進(AMGN.US)啓動了AMG 133(Maridebart Cafraglutide，MariTide)的兩項III期臨牀試驗(MARITIME-1和MARITIME-2)，標誌着AMG 133進入III期開發階段。AMG133是安進自主研發的一款注射頻率可達到每4周1次的first-in-class抗體多肽偶聯藥物，由靶向葡萄糖依賴性促胰島素釋放多肽受體(GIPR)的全人源單抗偶聯兩個GLP-1類似物而成，通過抑制GIPR並激活GLP-1受體(GLP-1R)來發揮減少食物攝入和調節代謝進而減輕體重和降低血糖的作用。AMG 133的降糖和減重效果已經在II期研究中得到了初步驗證。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}